ALK and non-small cell lung carcinoma: A recent study showed that local ablative therapy (radiation or surgery) and continuation of TKIs could extend disease control by >6 months in patients with ALK+ or EGFR‐MT NSCLC on erlotinib or crizotinib therapy who developed oligoprogressive disease.9